Trial Profile
Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score ' 4.5)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cytarabine; Daunorubicin; Idarubicin
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 03 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 29 May 2014 New trial record